PAINWeek 2019 Accepted Abstracts

Conclusions CNTX-6970 demonstrated acceptable safety and tolerability across the full dose range. In healthy adult male subjects, CNTX6970 exhibited a favorable pharmacokinetic profile and dose proportionality after a single oral dose (50 600 mg). CNTX6970 inhibited CCR2 and CCR5 receptor binding to their respective ligands. These results support further evaluation of CNTX6970 in patients.